Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Athira Pharma Inc (NQ: ATHA )

3.220 +0.170 (+5.57%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 1, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,372,772
Open 3.100
Bid (Size) 3.130 (1)
Ask (Size) 3.220 (40)
Prev. Close 3.050
Today's Range 3.010 - 3.320
52wk Range 2.530 - 16.65
Shares Outstanding 37,635,983
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
4 Analysts Have This to Say About Athira Pharma
Analysts have provided the following ratings for Athira Pharma (NASDAQ:ATHA) within the last quarter: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 23, 2022
Upgrades 
Via Benzinga

Performance

YTD
-75.27%
-75.27%
1 Month
-64.06%
-64.06%
3 Month
-75.79%
-75.79%
6 Month
-75.29%
-75.29%
1 Year
-69.59%
-69.59%

More News

Read More
Athira Pharma Shares Fall To 52-Week Low - Read Why
Via Benzinga
10 Biggest Price Target Changes For Thursday: Alcoa, Travelers And More
Via Benzinga
76 Biggest Movers From Yesterday: Ocean Bio-Chem, Athira Pharma And More
Via Benzinga
Dow Jumps 150 Points; Ocean Bio-Chem Shares Spike Higher
Via Benzinga
Stocks Quietly Higher as Market Attempts to Extend Rally
Via Talk Markets
U.S. Stocks Turn Higher; Athira Pharma Shares Plummet
Via Benzinga
40 Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Exela Technologies (XELA) Stock Soars After Securing $136 Million Contract
Via InvestorPlace
Athira Pharma (ATHA) Stock Plunges 65% on Disappointing Drug Trial Results
Via InvestorPlace
The Daily Biotech Pulse: Precision BioSciences Inks Gene Editing Pact, Athira Pharma's Alzheimer's Candidate Fails, Enanta Sues Pfizer Over COVID-19 Antiviral
Via Benzinga
Why Athira Pharma Stock Is Plunging
Via Benzinga
ATHIRA PHARMA INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Athira Pharma, Inc. - ATHA
From Kahn Swick & Foti, LLC
Via Business Wire
ATHIRA ALERT: Bragar Eagel & Squire, P.C. Is Investigating Athira Pharma, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For May 10, 2022
Via Benzinga
ATHIRA PHARMA INVESTIGATION CONTINUED By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Athira Pharma, Inc. - ATHA
From Kahn Swick & Foti, LLC
Via Business Wire
ATHIRA PHARMA INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Athira Pharma, Inc. - ATHA
From Kahn Swick & Foti, LLC
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For April 21, 2022
Via Benzinga
ATHIRA ALERT: Bragar Eagel & Squire, P.C. is Investigating Athira Pharma, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
The Daily Biotech Pulse: MEI Pharma Wilts On Adverse Regulatory Development, Decision Day For Zogenix, AN2 Therapeutics IPO
Via Benzinga
The Daily Biotech Pulse: Novartis Prostate Cancer Drug Lands FDA Approval, Ligand Announces SPAC Deal To Spin Off Antibody Business, Lilly's Lung Cancer Therapy Hit With CRL
Via Benzinga
Earnings Scheduled For March 24, 2022
Via Benzinga
Earnings Preview: Athira Pharma
Via Benzinga
The Week Ahead In Biotech (March 20-26): Focus On Zogenix FDA Decision, Dermatology Conference Presentations & Earnings
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.